Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?

Post time 2026-9-7 22:09:23

journal：Neuro-Oncology

Authors：Mustafa Khasraw; Matthew D Dun; Isabel Arrillaga-Romany; Roel G W Verhaak; Eric Bouffet; Jordan R Hansford; Kirit Singh; Sabine Mueller; Carl Koschmann; Patrick Y Wen

Published date：2026-8-1

DOI：10.1093/neuonc/noag117

PDF link：https://academic.oup.com/neuro-o ... 8370895/noag117.pdf

Article link：https://doi.org/10.1093/neuonc/noag117

Article Source：Oxford University Press (OUP)。

Remark：

Post time 2026-9-7 22:09:24

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Oxford] Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Oxford] Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step? Copy